WO2003022262A1 - Pharmaceutical composition comprising gamma-butyrobetaine - Google Patents
Pharmaceutical composition comprising gamma-butyrobetaine Download PDFInfo
- Publication number
- WO2003022262A1 WO2003022262A1 PCT/LV2002/000004 LV0200004W WO03022262A1 WO 2003022262 A1 WO2003022262 A1 WO 2003022262A1 LV 0200004 W LV0200004 W LV 0200004W WO 03022262 A1 WO03022262 A1 WO 03022262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- butyrobetaine
- gamma
- gbb
- thp
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- Invention relates to a second medical use of a known pharmaceutical agent and composition comprising thereof, particularly to normalize and stimulate sexual activity and potency in mammals.
- the invention discloses novel effects of known substances, showing in combination unexpected level of pharmacological activity.
- a pharmaceutical composition comprising as active ingredients gamma-butyrobetaine (GBB) in combination with 3-(2,2,2-trimethylhydrazinium)propionate (THP) or phosphodiesterase inhibitor.
- GBB actinine
- 3-(2,2,2-Trimethylhydrazinium)pro ⁇ ionate is known also as a medicine Mildronate or Quaterine (UK patent 2105992). It interferes with carnitine biosynthesis and, consequently, limits the transporting of long-chain fatty acids through mitochondrial membranes (Simkhovich BZ, Shutenko ZV, Meirena DV et al. 3-(2,2,2-trimethylhydrazinium)propionate (THP) - a novel ⁇ - butyrobetaine inhibitor with cardioprotective properties. Biochem Pharmacol 1988;37:195). It has therefore found application as metabolic corrector in ischemic diseases of different origin and cytoprotector in hypoxic conditions.
- a pharmaceutical composition for the treatment of cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium)propionate and gamma- butyrobetaine was disclosed in Moldovan patent LV 11728.
- gamma-butyrobetaine and/or THP induce substantial and long-lasting increase of sexual activity in laboratory animals. Moreover, the combination of both substances produce a more prolonged and higher increase of the intracavemous pressure than each of the constituent substances separately. Moreover, GBB or combination thereof with THP, exert a positive influence on intracavemous pressure, induced by reflectory stimulation. Thus we have unexpectedly discovered that GBB or combination thereof with THP, are useful for stimulating of both the sexual activity and potency of mammals. This activity can not be attributed to the known effects of GBB and/or THP on the fatty acids turnover or other known physiological effects of said substances.
- Group 1 Control Group
- Group 2 GBB Group
- gamma- butyrobetaine 0.015% by weight
- Group 3 (THP Group) - drinking water was supplemented by THP (0.06% by weight), resulting in the average daily THP intake of 60 mg/kg;
- Group 4 (GBB + THP Group) - drinking water was supplemented by THP (0.06% by weight) and gamma-butyrobetaine (0.015% by weight), resulting in the average daily THP intake of 60 mg/kg and gamma-butyrobetaine intake of 15 mg/kg.
- the copulating activity of male rats was tested four times: after one week, after four weeks, after six weeks and 48 - 50 hours after the discontinuation of substance intake, when all animals were receiving drinking water without additives.
- postcoital period the behaviour of male rats during 5 min. period after the removal of females.
- the postcoital behaviour was characterized by following marks: 0 - the animal is passive, lays down; 1 - the rat is quiet, grooming; 2 - the rat is mobile, rutting; 3 - the animal is active, aggressive.
- the female rats used were in the estrus phase, induced by i.p. injection of 0.2 ml 0.1% estradiol dipropionate ' 48 h before the test.
- Rats were anesthetized by sodium pentobarbital (50 mg/kg i.p. plus additionally 8 mg/kg/h i.v.). Body temperature was kept at 37 - 37.4 °C (rectal control) by heating lamp. Endotracheal tube was inserted to assure adequate respiration under anesthesia. Number 25 needle filled with heparinized saline was connected to pressure transducer and introduced into corpus cavemosum penis. Intracavemous pressure and II standard lead on an ECG was continuously recorded on physiograph DMP-4B (Narco Bio-Systems, USA). In some experiments arterial pressure in common carotid artery was also recorded. The effects of experimental substances were determined both at intravenous and intracavemous introduction route.
- GEB Gamma-butyrobetaine
- THP intracavemous injection 0.2 mg per rat; intravenously 10.0 mg/kg
- Sildenafil intracavemous injection 0.15 mg per rat, intravenously 3.0 mg/kg was introduced separately and in combination (GBB + sildenafil).
- GBB-THP in combination and GBB plus sildenafil sustains its effect 2.25 times or even, correspondingly, 5.46 times longer than the GBB alone. It is also essential to note that only GBB-THP in combination induced a pronounced positive response to reflex penis stimulation resulting in increase of intracorporeal pressure, a response untypical for narcotized animals.
- compositions containing GBB or combination thereof with THP or sildenafil produced an increase of intracorporeal pressure not only at intracavemous injection, but also, contrary to papaverine, at intravenous route.
- THP or sildenafil produced an increase of intracorporeal pressure not only at intracavemous injection, but also, contrary to papaverine, at intravenous route.
- the substances displayed orally are useful for stimulation of sexual activity and erection both at norm and at physiological depression of erectile function, being introduced both enterally and parenterally.
- the pharmaceutical composition contains the combination of gamma-butyrobetaine with THP or gamma- butyrobetaine with sildenafil in the summary amount of 0.5-40% by total weight of pharmaceutical form and distilled water, physiologic saline solution, glucose solution, or buffer solution as a pharmaceutically acceptable solvent.
- the pharmaceutical composition contains the combination of gamma-butyrobetaine with THP or gamma-butyrobetaine with sildenafil in the summary amount of 0.5 to 5 g by weight per tablet, caplet, capsule, pill, granule, or powder dosage unit.
- the pharmacutical composition may include other pharmacutical agents, such, as for example, other phosphodiesterase type V inhibitors (vardenafil, tadalafil and related).
- other phosphodiesterase type V inhibitors vardenafil, tadalafil and related.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020047003366A KR100841035B1 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
JP2003526391A JP4382480B2 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising γ-butyrobetaine |
MXPA04002050A MXPA04002050A (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine. |
DE60217369T DE60217369T2 (en) | 2001-09-07 | 2002-03-04 | PHARMACEUTICAL COMPOSITION CONTAINING GAMMA BUTYROBETAIN |
DK02702955T DK1429753T3 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
EA200400386A EA006675B1 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
AU2002236340A AU2002236340B2 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
CA2459719A CA2459719C (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
SI200230507T SI1429753T1 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
NZ532178A NZ532178A (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine for treating erectile dysfunction |
US10/488,840 US20040242590A1 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
IL16073402A IL160734A0 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
EP02702955A EP1429753B1 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
UA2004042511A UA78235C2 (en) | 2001-09-07 | 2002-04-03 | Pharmaceutical compositions, containing gamma-butyrobetaine for treating impotence in males of mammals |
IL160734A IL160734A (en) | 2001-09-07 | 2004-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine and use thereof |
HR20040328A HRPK20040328B3 (en) | 2001-09-07 | 2004-04-07 | Pharmaceutical composition comprising gamma-butyrobetaine |
HK05100218A HK1068003A1 (en) | 2001-09-07 | 2005-01-11 | Pharmaceutical composition comprising gamma-butyrobetaine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-01-00134 | 2001-09-07 | ||
LVP-01-134A LV12979B (en) | 2001-09-07 | 2001-09-07 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003022262A1 true WO2003022262A1 (en) | 2003-03-20 |
Family
ID=19735292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/LV2002/000004 WO2003022262A1 (en) | 2001-09-07 | 2002-03-04 | Pharmaceutical composition comprising gamma-butyrobetaine |
Country Status (30)
Country | Link |
---|---|
US (1) | US20040242590A1 (en) |
EP (1) | EP1429753B1 (en) |
JP (1) | JP4382480B2 (en) |
KR (1) | KR100841035B1 (en) |
CN (1) | CN1275595C (en) |
AR (1) | AR036423A1 (en) |
AT (1) | ATE350029T1 (en) |
AU (1) | AU2002236340B2 (en) |
BG (1) | BG108673A (en) |
CA (1) | CA2459719C (en) |
CU (1) | CU23347B6 (en) |
DE (1) | DE60217369T2 (en) |
DK (1) | DK1429753T3 (en) |
EA (1) | EA006675B1 (en) |
ES (1) | ES2280505T3 (en) |
HK (1) | HK1068003A1 (en) |
HR (1) | HRPK20040328B3 (en) |
IL (2) | IL160734A0 (en) |
JO (1) | JO2507B1 (en) |
LV (1) | LV12979B (en) |
MA (1) | MA27683A1 (en) |
MX (1) | MXPA04002050A (en) |
MY (1) | MY134074A (en) |
NZ (1) | NZ532178A (en) |
PL (1) | PL368758A1 (en) |
PT (1) | PT1429753E (en) |
SI (1) | SI1429753T1 (en) |
TW (1) | TWI224506B (en) |
WO (1) | WO2003022262A1 (en) |
ZA (1) | ZA200402702B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006022536A1 (en) * | 2004-08-24 | 2006-03-02 | Joint Stock Company 'grindeks' | New medical use of the meldonium |
JP2006527177A (en) * | 2003-06-06 | 2006-11-30 | ウニベルジテートスクリニクム フライブルク | Drug or pharmaceutical composition for prevention and / or treatment of portal hypertension |
WO2009095445A1 (en) * | 2008-01-29 | 2009-08-06 | Grindeks | New second medical use of 3-(2,2,2-trimethylhydrazine)propionate dihydrate |
RU2622757C1 (en) * | 2016-06-02 | 2017-06-19 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Method for erectile dysfunction treatment |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2324886A1 (en) | 2005-07-29 | 2011-05-25 | Concert Pharmaceuticals Inc. | Novel deuterated analogues of tadalafil |
CN101781302B (en) * | 2009-05-31 | 2013-07-10 | 段波 | Adduct generated from phosphodiesterase inhibitor and isoflavone and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4382092A (en) * | 1981-01-06 | 1983-05-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical composition comprising gamma-butyrobetaine for the treatment of syndromes induced by L-carnitine deficiency |
WO1997006794A1 (en) * | 1995-08-21 | 1997-02-27 | Ivars Kalvinsh | Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine |
WO1997006795A1 (en) * | 1995-08-21 | 1997-02-27 | Ivars Kalvinsh | Pharmaceutical compositions containing gamma-butyrobetain for treatment of blood flow disorders |
-
2001
- 2001-09-07 LV LVP-01-134A patent/LV12979B/en unknown
-
2002
- 2002-03-04 NZ NZ532178A patent/NZ532178A/en unknown
- 2002-03-04 CN CNB028175077A patent/CN1275595C/en not_active Expired - Fee Related
- 2002-03-04 DK DK02702955T patent/DK1429753T3/en active
- 2002-03-04 DE DE60217369T patent/DE60217369T2/en not_active Expired - Lifetime
- 2002-03-04 ES ES02702955T patent/ES2280505T3/en not_active Expired - Lifetime
- 2002-03-04 PT PT02702955T patent/PT1429753E/en unknown
- 2002-03-04 EP EP02702955A patent/EP1429753B1/en not_active Expired - Lifetime
- 2002-03-04 PL PL02368758A patent/PL368758A1/en unknown
- 2002-03-04 EA EA200400386A patent/EA006675B1/en not_active IP Right Cessation
- 2002-03-04 AU AU2002236340A patent/AU2002236340B2/en not_active Ceased
- 2002-03-04 WO PCT/LV2002/000004 patent/WO2003022262A1/en active IP Right Grant
- 2002-03-04 AT AT02702955T patent/ATE350029T1/en not_active IP Right Cessation
- 2002-03-04 IL IL16073402A patent/IL160734A0/en unknown
- 2002-03-04 KR KR1020047003366A patent/KR100841035B1/en not_active IP Right Cessation
- 2002-03-04 SI SI200230507T patent/SI1429753T1/en unknown
- 2002-03-04 US US10/488,840 patent/US20040242590A1/en not_active Abandoned
- 2002-03-04 JP JP2003526391A patent/JP4382480B2/en not_active Expired - Fee Related
- 2002-03-04 MX MXPA04002050A patent/MXPA04002050A/en active IP Right Grant
- 2002-03-04 CA CA2459719A patent/CA2459719C/en not_active Expired - Fee Related
- 2002-08-29 MY MYPI20023224A patent/MY134074A/en unknown
- 2002-09-04 AR ARP020103331A patent/AR036423A1/en unknown
- 2002-09-05 TW TW091120239A patent/TWI224506B/en not_active IP Right Cessation
- 2002-09-05 JO JO200291A patent/JO2507B1/en active
-
2004
- 2004-03-04 IL IL160734A patent/IL160734A/en not_active IP Right Cessation
- 2004-03-04 CU CU20040040A patent/CU23347B6/en unknown
- 2004-04-05 MA MA27608A patent/MA27683A1/en unknown
- 2004-04-06 ZA ZA200402702A patent/ZA200402702B/en unknown
- 2004-04-07 HR HR20040328A patent/HRPK20040328B3/en not_active IP Right Cessation
- 2004-04-07 BG BG108673A patent/BG108673A/en unknown
-
2005
- 2005-01-11 HK HK05100218A patent/HK1068003A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4382092A (en) * | 1981-01-06 | 1983-05-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical composition comprising gamma-butyrobetaine for the treatment of syndromes induced by L-carnitine deficiency |
WO1997006794A1 (en) * | 1995-08-21 | 1997-02-27 | Ivars Kalvinsh | Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine |
WO1997006795A1 (en) * | 1995-08-21 | 1997-02-27 | Ivars Kalvinsh | Pharmaceutical compositions containing gamma-butyrobetain for treatment of blood flow disorders |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527177A (en) * | 2003-06-06 | 2006-11-30 | ウニベルジテートスクリニクム フライブルク | Drug or pharmaceutical composition for prevention and / or treatment of portal hypertension |
JP2009280602A (en) * | 2003-06-06 | 2009-12-03 | Universitaetsklinikum Freiburg | Prophylaxis and/or treatment of portal hypertension |
JP2010195821A (en) * | 2003-06-06 | 2010-09-09 | Universitaetsklinikum Freiburg | Prophylaxis and/or treatment of portal hypertension |
US9278097B2 (en) | 2003-06-06 | 2016-03-08 | Universitatsklinikum Freiburg | Prophylaxis and/or treatment of portal hypertension |
WO2006022536A1 (en) * | 2004-08-24 | 2006-03-02 | Joint Stock Company 'grindeks' | New medical use of the meldonium |
WO2009095445A1 (en) * | 2008-01-29 | 2009-08-06 | Grindeks | New second medical use of 3-(2,2,2-trimethylhydrazine)propionate dihydrate |
RU2622757C1 (en) * | 2016-06-02 | 2017-06-19 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) | Method for erectile dysfunction treatment |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2925326B2 (en) | Methods for promoting human nitrogen retention | |
US7790688B2 (en) | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly | |
JPS58154511A (en) | Weight reducing agent | |
WO1991007188A1 (en) | Method for reducing blood cholesterol using arginine | |
JP2003171271A (en) | Medicine for glucose tolerance disorder | |
CA2459719C (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
AU2002236340A1 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
ES2271042T3 (en) | FOOD SUPPLEMENT WITH A SLIMMING EFFECT. | |
JPH04506667A (en) | Thyroid hormone cardiac therapy | |
JP2002512191A (en) | A composition comprising L-carnitine or alkanoyl L-carnitine and NADH and / or HADPH. | |
WO2003022263A1 (en) | Pharmaceutical composition comprising gamma-butyrobetaine for stimulating the sexual activity and potency | |
US3658968A (en) | Composition and method of treatment | |
WO2017144978A1 (en) | Optically active acetylamino acid salts of (1r,2r,3s)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane and their use in the treatment of obesity | |
RU2165759C1 (en) | Method for treating alcohol intoxication | |
US6441039B1 (en) | Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement | |
WO2023156275A1 (en) | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor | |
JPH06102624B2 (en) | Anti-arrhythmic drugs of non-heart origin | |
US20050250674A1 (en) | Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs | |
WO2003026634A1 (en) | Amines with antialcoholic agents | |
US3298916A (en) | Treatment and composition for high blood pressure and palpitation | |
EP1455774A1 (en) | Pharmaceutical composition for treating obesity | |
JPH0440328B2 (en) | ||
JPS59184124A (en) | Agent for improving energy metabolism | |
UA48470A (en) | The biologically active preparation “KARDONAT ” |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200400293 Country of ref document: VN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/002050 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2459719 Country of ref document: CA Ref document number: 10488840 Country of ref document: US Ref document number: 160734 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003526391 Country of ref document: JP Ref document number: 1020047003366 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028175077 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200400386 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 446/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002702955 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/02702 Country of ref document: ZA Ref document number: 2002236340 Country of ref document: AU Ref document number: 532178 Country of ref document: NZ Ref document number: 200402702 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 10867302 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PK20040328A Country of ref document: HR Ref document number: 108673 Country of ref document: BG |
|
WWP | Wipo information: published in national office |
Ref document number: 2002702955 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-500336 Country of ref document: PH |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002702955 Country of ref document: EP |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0212629 Country of ref document: BR Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 07.05.2003 ( 20 MESES - BR DESIGNADO APENAS), ELEICAO NAO COMPROVADA, E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 01.03.2004. |